Cardiol Therapeutics (CRDL) Stock Overview
A clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CRDL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cardiol Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.00 |
| 52 Week High | CA$1.59 |
| 52 Week Low | CA$0.77 |
| Beta | 0.82 |
| 1 Month Change | 0.69% |
| 3 Month Change | -14.53% |
| 1 Year Change | -22.48% |
| 3 Year Change | 42.86% |
| 5 Year Change | -59.02% |
| Change since IPO | -73.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRDL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.7% | 1.2% | -0.4% |
| 1Y | -22.5% | 27.6% | 12.7% |
Return vs Industry: CRDL underperformed the US Pharmaceuticals industry which returned 27.6% over the past year.
Return vs Market: CRDL underperformed the US Market which returned 12.7% over the past year.
Price Volatility
| CRDL volatility | |
|---|---|
| CRDL Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRDL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRDL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 18 | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
| CRDL fundamental statistics | |
|---|---|
| Market cap | US$114.88m |
| Earnings (TTM) | -US$25.37m |
| Revenue (TTM) | n/a |
Is CRDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$34.78m |
| Earnings | -CA$34.78m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRDL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 23:57 |
| End of Day Share Price | 2026/01/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardiol Therapeutics Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tyler Bussian | Brookline Capital Markets |
| Edward Nash | Canaccord Genuity |
| Christian Orquera | First Berlin Equity Research GmbH |